Synairgen files for another patent on 'SNG001'
(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.
Read moreWed, 05th Aug 2015 10:21
(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.
Read moreIN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial
Read more(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.
Read moreIN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line
Read moreBy Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...
Read moreLONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News
Read moreSynairgen Shares Soar On Positive Trial Results For Covid-19 Treatment
Read more* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...
Read more(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...
Read more(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...
Read more(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.
Read moreJuly 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...
Read more(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001
Read more